Whether these differences are related to tumour genotype and the presence of somatic mutations of NRF2 [27–29] is an interesting possibility, but further studies are required to address these possibilities; iii) thirdly, HCC patients with the highest induction of MT1 have reduced overall survival under sorafenib treatment, suggesting the possibility that the alteration of the redox metabolism of cancer cells might be detrimental to HCC patients receiving sorafenib. The gene discussed is MT1E; the disease is neoplasm.